Hemogenyx Pharmaceuticals Statistics

Total Valuation

LON:HEMO has a market cap or net worth of GBP 46.24 million. The enterprise value is 46.61 million.

Market Cap	46.24M
Enterprise Value	46.61M

Important Dates

The next estimated earnings date is Friday, September 25, 2026.

Earnings Date	Sep 25, 2026
Ex-Dividend Date	n/a

Share Statistics

LON:HEMO has 6.80 million shares outstanding. The number of shares has increased by 73.29% in one year.

Current Share Class	6.80M
Shares Outstanding	6.80M
Shares Change (YoY)	+73.29%
Shares Change (QoQ)	+0.01%
Owned by Insiders (%)	16.05%
Owned by Institutions (%)	56.11%
Float	5.06M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	40.40
P/TBV Ratio	45.63
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-4.78
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-13.50

Financial Position

The company has a current ratio of 1.38, with a Debt / Equity ratio of 1.75.

Current Ratio	1.38
Quick Ratio	1.38
Debt / Equity	1.75
Debt / EBITDA	n/a
Debt / FCF	-0.58
Interest Coverage	-30.38

Financial Efficiency

Return on equity (ROE) is -977.71% and return on invested capital (ROIC) is -131.56%.

Return on Equity (ROE)	-977.71%
Return on Assets (ROA)	-103.92%
Return on Invested Capital (ROIC)	-131.56%
Return on Capital Employed (ROCE)	-257.66%
Weighted Average Cost of Capital (WACC)	11.99%
Revenue Per Employee	n/a
Profits Per Employee	-610,023
Employee Count	16
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +268.89% in the last 52 weeks. The beta is 1.43, so LON:HEMO's price volatility has been higher than the market average.

Beta (5Y)	1.43
52-Week Price Change	+268.89%
50-Day Moving Average	948.90
200-Day Moving Average	782.01
Relative Strength Index (RSI)	31.30
Average Volume (20 Days)	31,016

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-6.97M
Pretax Income	-9.77M
Net Income	-9.76M
EBITDA	-6.38M
EBIT	-6.97M
Earnings Per Share (EPS)	-1.71

Full Income Statement

Balance Sheet

The company has 1.59 million in cash and 2.00 million in debt, with a net cash position of -417,816 or -0.06 per share.

Cash & Cash Equivalents	1.59M
Total Debt	2.00M
Net Cash	-417,816
Net Cash Per Share	-0.06
Equity (Book Value)	1.14M
Book Value Per Share	0.15
Working Capital	564,875

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -3.45 million and capital expenditures -3,921, giving a free cash flow of -3.45 million.

Operating Cash Flow	-3.45M
Capital Expenditures	-3,921
Depreciation & Amortization	588,753
Net Borrowing	-632,575
Free Cash Flow	-3.45M
FCF Per Share	-0.51

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

LON:HEMO does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-73.29%
Shareholder Yield	-73.29%
Earnings Yield	-21.11%
FCF Yield	-7.47%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on December 13, 2024. It was a reverse split with a ratio of 0.0025.

Last Split Date	Dec 13, 2024
Split Type	Reverse
Split Ratio	0.0025

Scores

Altman Z-Score	n/a
Piotroski F-Score	2